Next-Generation Solution for Genomic Profiling

Oncomine Solutions on the Ion Torrent Genexus System feature a complete next-generation sequencing (NGS) testing workflow. Now every lab can go from specimen to report in a single day, providing a comprehensive genomic profile at a speed never possible before.* This allows you to deliver NGS results at the same time as other single-gene methods such as immunohistochemistry (IHC). The hands-off, set-up-and-go workflow makes NGS accessible even if your lab is new to the technology. With the lowest sample input requirement of any NGS solution, you can successfully sequence more of the samples that come through your lab.

Register for webinar  

Oncomine assays for the Genexus System

a46291-oncomine-precison-assay-gx (1)

Oncomine Precision Assay

The Oncomine Precision Assay features carefully curated biomarker content spanning 50 genes. Enhanced fusion detection provides broad coverage for the most prevalent isoforms, along with novel fusions. You have the option to profile DNA or RNA from lysate or plasma, giving you a wide range of utility. All of this is provided with a single-day turnaround time and a highly automated workflow on the Genexus System.

Download the flyer to see the complete gene list ›

Don’t let precious samples go untested

Did you know that some NGS send-out labs have test failure rates of 20% due to their high input requirement (1-4)? At that rate, one out of every five samples submitted will not pass due to lack of tissue, and many more are never submitted for testing at all. Not with Oncomine Solutions. You can experience a sequencing success rate of over 95% because we only require 10 ng of nucleic acid input. This means you can get an NGS result for most of the precious samples you have.


Maximize your ability to detect key biomarkers

Curated pan-cancer content

FusionSyncTM detection technology

Molecular tagging

Tissue and plasma samples

magnifying glass_DNA
  • Mutation, CNV, and fusion variant types across 50 key genes
  • Tumor suppressors, driver and resistance variants
fusion sync detection
  • Sensitive and specific—targeted isoform designs
  • Novel fusion detection
molecular tagging
  • Enhanced low-level variant detection
  • Key for liquid biopsy testing
tissue_plasma sample
  • One test, one workflow, multiple sample types
  • Maximizes the number of tumors that can be profiled

All you need to know about Oncomine Precision Assay in 30 seconds: download the infographic ›

FusionSync detection technology

Gene fusions are an increasingly important target in precision oncology. Oncomine assays are superior for both sequencing success rate and sensitivity, two critical factors for fusion detection. Even when tissue is very limited or the variants exist at low levels in the sample, you can detect key fusions by combining:

  • Targeted known fusion detection
  • Non-targeted detection of novel fusion combinations
  • Novel fusion detection

Webinar: Introducing a new world of NGS: one-day, hands-free solution to fit in any lab

December 5, 2019 | 11:00 am EST/16:00 GMT

  • Learn how the Genexus System addresses key challenges to NGS adoption
  • See the next-generation solution for genomic profiling of cancer samples
  • Hear about the experience of the first laboratory to implement this solution: IPATIMUB in Portugal

Register today ›


Dr. Jose Costa, IPATIMUB

Dr. Andy Felton, Thermo Fisher Scientific

Advancing Precision Oncology

NGS is the platform of choice for genomic profiling. The days of having to run multiple single gene tests are over. You no longer have to settle for time delays and depletion of tissue. With NGS, you can assess multiple biomarkers simultaneously in a single test for a comprehensive molecular profile, all while preserving tissue.  Visit our educational website to learn how NGS is helping advance precision oncology from research to reality.

Learn more ›

Request a quote



1. Davis W, et al. Next-Generation Sequencing in 305 Consecutive Patients: Clinical Outcomes and Management Changes. J Oncol Pract. 2019 Aug 2:JOP1900269.
2. Ready N, et al. First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers. J Clin Oncol. 2019 Apr 20;37(12):992-1000.
3. Zhu J, et al. Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer. Urol Oncol. 2019 Jul 18. pii: S1078-1439(19)30244-3.
4. Heeke S, et al. Abstract 4889: Comparison of tumor mutational burden using the Ion Oncomine TML and FoundationOne assays with routine clinical FFPE tissue samples to predict durable clinical benefit in lung cancer and melanoma patients - a multivariate analysis integrating PD-L1 and CD8+ evaluation. Proceedings: AACR Annual Meeting 2019. DOI: 10.1158/1538-7445.AM2019-4889.  

* Specimen-to-report workflow will be available after the Ion Torrent™ Genexus™ Purification System and integrated reporting capabilities are added in 2020.